Answers are grounded in this paper and cite their sources.
Photoimmunotherapy (PIT) has emerged as a promising modality for colorectal cancer (CRC) treatment, yet it often suffers from limited response rates and immune escape. We herein report a carrier‐free, tumor‐specific nanomodulator (IRP@Cu‐R) for near‐infrared second window (NIR‐II) fluorescence imaging‐guided cuproptosis‐augmented PIT of CRC. IRP@Cu‐R is prepared by co‐assembly of IRP@Cu, which is synthesized by linking a NIR‐II fluorophore (IR820) with a photosensitizer (PPa) through Cu 2+ ‐chelated DTPA, and a boronic ester‐masked immune adjuvant (R848‐PB) without additional nanocarrier. The drug loading contents for PPa and R848‐PB are as high as 21.1% and 17.8%, respectively. With Cu 2+ coordinated, both NIR‐II fluorescence and photodynamic activity are quenched via photoinduced electron transfer (PeT). Upon exposure to endogenous hydrogen sulfide (H 2 S), Cu 2+ is converted to CuS, thereby restoring both activities. The released Cu 2+ is reduced to Cu + by glutathione (GSH), depleting antioxidants and inducing cuproptosis via lipoylated protein aggregation. Together with PDT, this process enhances immunogenic cell death. Meanwhile, excess H 2 O 2 cleaves the boronic ester bond of R848‐PB to release R848. These processes promote dendritic cell maturation, thereby eliciting potent systemic antitumor immunity against primary, distant and metastatic tumors. Thus, this study provides a generalizable carrier‐free strategy for integrating activatable NIR‐II fluorescence imaging with cuproptosis‐augmented photoimmunotherapy.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: